Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today the results of voting at its annual meeting of shareholders held earlier today (the “Meeting”). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of Greenbrook dated May 19, 2020.

The total number of common shares represented by holders by proxy at the Meeting was 20,536,883, representing approximately 30.42% of Greenbrook’s outstanding common shares entitled to be voted.

Election of Directors

All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed, without a ballot being conducted. The following represents the proxies received with regard to such matter:

Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

Brian P. Burke

19,157,451

99.98%

3,000

0.02%

Colleen Campbell

19,160,451

100.00%

0

0.00%

Sasha Cucuz

19,157,451

99.98%

3,000

0.02%

Adrienne Graves, Ph.D.

19,157,451

99.98%

3,000

0.02%

Bill Leonard

19,157,451

99.98%

3,000

0.02%

Adele C. Oliva

19,160,451

100.00%

0

0.00%

Frank Tworecke

19,157,451

99.98%

3,000

0.02%

Elias Vamvakas

19,149,451

99.94%

11,000

0.06%

Appointment of Auditors

KPMG LLP was reappointed as auditor of Greenbrook and the directors were authorized to fix the auditor’s remuneration by a resolution passed by a majority of the shareholders represented by proxy at the Meeting, without a ballot being conducted. The following represents the proxies received with regard to such matter:

Votes For

% Votes For

Votes Withheld

% Votes Withheld

20,533,883

99.99%

3,000

0.01%

About Greenbrook TMS Inc.

Operating through 124 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 420,000 TMS treatments to over 11,000 patients struggling with depression.

Erns Loubser Chief Financial Officer and Treasurer Greenbrook TMS Inc.

Glen Akselrod Investor Relations Greenbrook TMS Inc. Contact Information: investorrelations@greenbrooktms.com 1-855-797-4867

Greenbrook TMS (TSX:GTMS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Greenbrook TMS Charts.
Greenbrook TMS (TSX:GTMS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Greenbrook TMS Charts.